Published in J Clin Oncol on October 20, 2014
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol (2015) 1.76
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. J Clin Oncol (2015) 1.71
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol (2016) 1.54
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One (2015) 1.38
Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. J Clin Oncol (2017) 1.37
Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ (2015) 1.03
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget (2016) 1.00
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol (2016) 0.92
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 0.88
Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction. Oncologist (2015) 0.85
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget (2016) 0.85
Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Oncologist (2016) 0.84
Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. Springerplus (2016) 0.83
New Frameworks to Assess Value of Cancer Care: Strengths and Limitations. Oncologist (2016) 0.83
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol (2016) 0.81
Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med (2015) 0.80
Treatment of early-stage HER2+ breast cancer-an evolving field. Ecancermedicalscience (2015) 0.79
Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol (2015) 0.79
Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. J Clin Oncol (2016) 0.79
Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer. Oncotarget (2015) 0.78
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget (2015) 0.77
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J Cancer Res (2016) 0.77
Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast Care (Basel) (2015) 0.77
Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells. Cancer Sci (2015) 0.76
Has racial difference in cause-specific death improved in older patients with late-stage breast cancer? Ann Oncol (2015) 0.76
Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel) (2016) 0.75
SEOM clinical guidelines in early-stage breast cancer 2015. Clin Transl Oncol (2015) 0.75
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget (2017) 0.75
Transtuzumab induced organizing pneumonia: a case report. Springerplus (2016) 0.75
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. Breast Cancer Res (2017) 0.75
Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol (2016) 0.75
Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. Ther Adv Med Oncol (2016) 0.75
HER2-Orientated Therapy in Early and Metastatic Breast Cancer. Breast Care (Basel) (2016) 0.75
True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer. Cureus (2016) 0.75
Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. Onco Targets Ther (2015) 0.75
Expression of integrin-binding protein Nischarin in metastatic breast cancer. Mol Med Rep (2015) 0.75
Adjuvant Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Oncologist (2015) 0.75
Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist (2016) 0.75
Recent advances in the medical treatment of breast cancer. F1000Res (2016) 0.75
Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. J Clin Oncol (2016) 0.75
Can ErbB2 overexpression protect against doxorubicin cardiotoxicity? Am J Physiol Heart Circ Physiol (2015) 0.75
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer (2017) 0.75
Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy. World J Clin Oncol (2016) 0.75
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol (2016) 0.75
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol (2016) 0.75
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press) (2015) 0.75
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. PLoS Med (2016) 0.75
Usefulness of miRNA profiles for predicting pathological responses to neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer. Oncol Lett (2017) 0.75
Breast cancer: The debate over post-mastectomy radiotherapy should continue. Nat Rev Clin Oncol (2015) 0.75
Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS One (2017) 0.75
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging (2015) 0.75
Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis. J Exp Clin Cancer Res (2017) 0.75
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Ann Surg Oncol (2016) 0.75
Dendrimer antibody conjugate to target and image HER-2 overexpressing cancer cells. Oncotarget (2016) 0.75
Breast-conserving therapy and modified radical mastectomy for primary breast carcinoma: a matched comparative study. Chin J Cancer Res (2015) 0.75
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc (2017) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment. Clin Exp Metastasis (2016) 0.75
Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst Rev (2017) 0.75
FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells. Exp Ther Med (2017) 0.75
Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness. Sci Rep (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39